Skip to main content
Clinical Trials/NCT05801471
NCT05801471
Recruiting
Not Applicable

An Observational Prospective Longitudinal Study for the Clinical Evaluation of Visual Field Change in Glaucoma. An Assessment of Different Models of Progression

Centervue SpA2 sites in 1 country200 target enrollmentMay 6, 2022
ConditionsGlaucoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glaucoma
Sponsor
Centervue SpA
Enrollment
200
Locations
2
Primary Endpoint
Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.

Registry
clinicaltrials.gov
Start Date
May 6, 2022
End Date
November 6, 2028
Last Updated
4 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Glaucomatous optic nerve head in both eyes;
  • Age between 40 and 90 years;
  • Best Corrected Visual Acuity ≤ 0.3 \[logMar\];
  • Spherical refraction between -6D and +6D;
  • Astigmatism between -2D and +2D.

Exclusion Criteria

  • Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment;
  • Any ocular pathology that can affect visual field other than glaucoma;
  • Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss;
  • Inability to obtain reliable perimetric examinations;
  • Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.

Outcomes

Primary Outcomes

Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).

Time Frame: 1 visit every 4 months (10 visits total), up to 3 years

Equivalence will be defined as the 95% confidence Intervals of the mean difference between the slopes estimated with the two devices being within ± 0.1 dB/year

Secondary Outcomes

  • Quantification of the effect of the integration of the rate of progression of structural metrics into the calculation of the rate of progression of the MD(1 visit every 4 months (10 visits total), up to 3 years)
  • Difference in time to identify progression between Compass and HFA using an event analysis(1 visit every 4 months (10 visits total), up to 3 years)

Study Sites (2)

Loading locations...

Similar Trials